Clinical Trial Update: Anti-RSV Study in Chinese Patients (ASCENT) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for an anti-RSV study conducted in Chinese patients (ASCENT) with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Snippet

Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd. | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: UNKNOWN